These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 16316312)

  • 1. Levosimendan for the treatment of acute heart failure syndromes.
    Parissis JT; Filippatos G; Farmakis D; Adamopoulos S; Paraskevaidis I; Kremastinos D
    Expert Opin Pharmacother; 2005 Dec; 6(15):2741-51. PubMed ID: 16316312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties.
    Lehtonen LA
    Expert Opin Investig Drugs; 2001 May; 10(5):955-70. PubMed ID: 11322869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart.
    Paraskevaidis IA; Parissis JT; Th Kremastinos D
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Jul; 3(3):243-7. PubMed ID: 15974888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
    Prijić S; Rakić S; Nikolić L; Jovicić B; Stajević M; Vukomanović V; Kosutić J
    Vojnosanit Pregl; 2011 Nov; 68(11):979-84. PubMed ID: 22191317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levosimendan: a novel agent in heart failure.
    Koumallos N; Antoniades C; Tousoulis D; Shirodaria C; Stefanadis C
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):185-91. PubMed ID: 18221085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan.
    Papp Z; Csapó K; Pollesello P; Haikala H; Edes I
    Cardiovasc Drug Rev; 2005; 23(1):71-98. PubMed ID: 15867949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.
    Lehtonen L
    Curr Heart Fail Rep; 2004 Sep; 1(3):136-44. PubMed ID: 16036037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan: a new dual-action drug in the treatment of acute heart failure.
    Mebazaa A; Erhardt L
    Int J Clin Pract; 2003 Jun; 57(5):410-6. PubMed ID: 12846347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
    Nieminen MS; Sandell EP
    Ital Heart J; 2003 May; 4 Suppl 2():39S-44S. PubMed ID: 14635369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: a case series.
    Malliotakis P; Xenikakis T; Linardakis M; Hassoulas J
    Hellenic J Cardiol; 2007; 48(2):80-8. PubMed ID: 17489345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM; Akhter MW
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock.
    Oldner A; Konrad D; Weitzberg E; Rudehill A; Rossi P; Wanecek M
    Crit Care Med; 2001 Nov; 29(11):2185-93. PubMed ID: 11700420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.